Agile Therapeutics Announces New Agreement With VitaCare Prescription Services To Improve Access To Twirla; Expanding Commercial Reach Through Partnerships Continues To Drive Company's Belief In Achieving 2023 Net Revenue In The Range Of $25M-$30M
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics has announced a new agreement with VitaCare Prescription Services, a subsidiary of GoodRx, to improve access to Twirla and streamline fulfillment. The partnership is expected to drive growth in the retail channel and contribute to Agile's 2023 net revenue target of $25-$30 million.
June 13, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agile Therapeutics' new partnership with VitaCare is expected to improve access to Twirla and contribute to the company's 2023 net revenue target of $25-$30 million.
The partnership with VitaCare is expected to improve access to Twirla, Agile's contraceptive product, and streamline fulfillment. This will likely drive growth in the retail channel, which is Agile's most profitable channel. The partnership aligns with Agile's strategy to grow Twirla through partnerships and is expected to contribute to the company's 2023 net revenue target of $25-$30 million. As a result, this news is likely to have a positive short-term impact on Agile's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100